drugset / Trial / NCT00245856

Treatment of Upper Extremity Deep-Vein Thrombosis

NCT00245856

Phase 4 Completed 67 enrolled University of Oklahoma Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.

Timeline

Start
2002-09
Primary completion
2009-03
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified 150 iu/kg Subcutaneous
Subject Dalteparin sodium Other / unclassified 200 iu/kg Subcutaneous
Subject Warfarin Small molecule